🇺🇸 FDA
Patent

US 11834649

CRISPR/CAS-related methods and compositions for treating herpes simplex virus

granted A61PA61P27/02A61P31/22

Quick answer

US patent 11834649 (CRISPR/CAS-related methods and compositions for treating herpes simplex virus) held by Editas Medicine, Inc. expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P27/02, A61P31/22